Amylyx: avexitide cut post-bariatric hypoglycemia events 55% versus placebo
In the phase III LUCIDITY trial, avexitide reduced level 2 and 3 hypoglycemic events by 55% versus placebo, according to TradingView. The NDA filing remains on schedule.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Amylyx's avexitide reduced composite level 2 and level 3 hypoglycemic events by 55% compared with placebo in the phase III LUCIDITY study in post-bariatric hypoglycemia (PBH). The condition is often undiagnosed, and no approved therapy exists for it yet.
The company reported that the drug also met its secondary endpoints and was generally well tolerated. Amylyx said its new drug application submission remains on track.
why it matters
For Amylyx investors, the readout is a key regulatory and commercial milestone: a clear efficacy result in a condition with no approved treatments shapes how the filing and any future launch will be judged. Data from a single trial, however, still carry regulatory and development risk until the agency reviews the application.
market impact
AMLX: positive phase III data and an on-track NDA support the company's shares
- Amylyx shares (AMLX) pressure up — positive phase III efficacy data lower development risk for avexitide
tags
instruments
sources
- AMLX: Avexitide cut PBH hypoglycemic events 55% vs placebo in phase III LUCIDITY — TradingView, 15 November 2026 at 21:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗